Tue, Sep 16, 2014, 3:51 AM EDT - U.S. Markets open in 5 hrs 39 mins

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • mayhem99 mayhem99 Jun 6, 1999 9:19 AM Flag

    isisadmirer

    You say "Nucleo/cyclix do not give a balanced view on Isis." and you say your only interest in ISIS is in shorting it. Maybe your the one that is giving the unbalanced vier.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Can't get it today. They must have bleeped it out.

    • among other things - more recognition from a major pharm company, continued funding - important since biotech ipo mkt is blah, and more validation of isis' potential...

    • YOU ZIGED WHEN YOU SHOULD HAVE ZAGED!

    • What does this agreement mean to us shareholders?

    • filing in regards to collaborative agreement between isis and Elan.

    • In early 1995 I purchased and still own stock in
      HGSI, MEDI and ISIP. The reason was to cover the human
      body by gene, vaccine and antisense. I had never heard
      of antisense but because of Human Genome Sciences
      indepth collaboration with ISIS I bought ISIP. My
      question is, due to your knowledge of Isis can you inform
      me what happen? This collaboration was apparently
      shot very quietly. Was it technical, business or
      personal?

      My purpose for knowing is-just trying to complete
      the total picture (connections) of my investments and
      avoid tunnel vision. Please see post #4108. Thanks.

    • You are absolutely right about ISIS receiving
      orphan drug status. Since ISIS will show that the
      end-points for its ISIS 2302 trials are anticipated to
      effect only a "segment" of the Crohn's disease market
      (perhaps just 200,000 potential patients), they should
      experience little difficulty in acquiring orphan drug
      status. i.e., They will demonstrate that ISIS 2302 is
      *steroid sparing* and *symptom relieving.*

      Not all
      Crohn's patients, however, require steroids. Therefore,
      technically, those that don't are not candidates for a steroid
      sparing drug. However, in practice, patients who discover
      ISIS 2302 to be the most effective among all available
      therapeutics in addressing their Crohn's symptoms, will employ
      it, regardless of whether or not they are steroid
      dependent. This may well mean that the market for ISIS 2302
      will realistically be substantially larger than the
      aforementioned 200,000 patients.

      Nucleotide String

    • Yes it's true, new customer's to PlanetRX will
      receive three free products from the list below! You
      only
      pay for $3.95 for shipping and handling! Choose
      three product's from the link below, and you'll
      have
      taken advantage of one of the best deals
      available on the net!


      http://www.planetrx.com/3forfree/3forfree.asp?mi=3wJE65nlUCU%3D



      Disclaimer: I am not affiliated with PlanetRX in
      any way! I do receive two
      products for passing
      this along, as you will if you pass it to your
      friends. If you
      use this link to sign up, email me at
      spxplayer@yahoo.com and I will send you
      a link to Drugstore.com
      for $15 in free products of your choice! Thanks
      and
      sorry for the intrusion!

    • for your informative reply to my post. What is
      the current thinking on the use of oligonucleotides
      for antisense therapy as a platform from which to
      launch treatments? Is there excitement about it? For
      instance, does anyone know if Novartis has discussions with
      ISIS about further collaborations? Are other big
      pharma companies talking with ISIS? Thanks again.

    • Filing;

      8K Filing = Unscheduled material events.
      8K/A = Amended report of Unscheduled material event. eom

    • View More Messages
 
ISIS
38.84-2.45(-5.93%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT
Tesla Motors, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT